Dimerix (DXB) Investor presentation summary

Strategic focus and innovation

• Developing novel therapies for kidney diseases with significant unmet clinical needs, targeting both rare and high-risk indications.

• Emphasizing diversification by geography and asset to reduce risk and enhance growth opportunities.

• Integrating ESG principles into business operations and decision-making.

Product pipeline and clinical progress

• DMX-200 is in Phase 3 for focal segmental glomerulosclerosis (FSGS), with recruitment completed and strong statistical power for efficacy.

• DMX-652, a first-in-class USP30 inhibitor, is Phase 2 ready for acute kidney injury (AKI) in high-risk cardiac surgery patients, with a strong safety profile and FDA clearance.

• Both assets leverage shared renal expertise and infrastructure, supporting efficient development and commercialization.

Commercial partnerships and revenue potential

• Five commercial licensing partners for DMX-200 across major global markets, with deals valued up to AU $1.9 billion in upfront, milestone payments, and royalties.

• Geographic diversification of revenue streams, with upfront and milestone payments totaling AU $318 million pre-launch.

• Royalties range from 10% to 30% depending on territory and partner.